| P50 | author | Katherine Frost | Q60315442 |
| | Robert W. Buchanan | Q109937282 |
| P2093 | author name string | Gregory P Strauss | |
| | James M Gold | |
| | William R Keller | |
| | James I Koenig | |
| P2860 | cites work | Diminished plasma oxytocin in schizophrenic patients with neuroendocrine dysfunction and emotional deficits | Q30492008 |
| | Different antipsychotics elicit different effects on magnocellular oxytocinergic and vasopressinergic neurons as revealed by Fos immunohistochemistry | Q33506130 |
| | The brief negative symptom scale: psychometric properties | Q33608454 |
| | Oxytocin-augmented social cognitive skills training in schizophrenia | Q33923629 |
| | Effects of adjunctive intranasal oxytocin on olfactory identification and clinical symptoms in schizophrenia: results from a randomized double blind placebo controlled pilot study | Q34015372 |
| | Adjunctive intranasal oxytocin reduces symptoms in schizophrenia patients | Q34023024 |
| | Chlorpromazine equivalent doses for the newer atypical antipsychotics | Q34208233 |
| | Peripheral oxytocin is associated with reduced symptom severity in schizophrenia | Q34311629 |
| | Reduced levels of vasopressin and reduced behavioral modulation of oxytocin in psychotic disorders | Q34322999 |
| | Oxytocin administration enhances controlled social cognition in patients with schizophrenia | Q34790823 |
| | Sex-specific associations between peripheral oxytocin and emotion perception in schizophrenia | Q35115758 |
| | Plasma oxytocin levels predict olfactory identification and negative symptoms in individuals with schizophrenia | Q35117441 |
| | Emotion recognition and oxytocin in patients with schizophrenia | Q35647312 |
| | Next-generation negative symptom assessment for clinical trials: validation of the Brief Negative Symptom Scale | Q36412864 |
| | Factor structure of the Brief Negative Symptom Scale | Q36412889 |
| | Peripheral vasopressin but not oxytocin relates to severity of acute psychosis in women with acutely-ill untreated first-episode psychosis | Q36756329 |
| | Characterization of the effects of oxytocin on fear recognition in patients with schizophrenia and in healthy controls | Q37022856 |
| | Differential correlations between plasma oxytocin and social cognitive capacity and bias in schizophrenia | Q39427998 |
| | Oxytocin does not improve performance of patients with schizophrenia and healthy volunteers in a facial emotion matching task | Q47819695 |
| | Divergent effects of two different doses of intranasal oxytocin on facial affect discrimination in schizophrenic patients with and without polydipsia | Q48154990 |
| | A pilot six-week randomized controlled trial of oxytocin on social cognition and social skills in schizophrenia | Q48300211 |
| | Effects of single dose intranasal oxytocin on social cognition in schizophrenia. | Q48474567 |
| | Improving social perception in schizophrenia: the role of oxytocin. | Q50536020 |
| | Sharing secrets: oxytocin and trust in schizophrenia. | Q51887808 |
| | Vasopressin--oxytocin in cerebrospinal fluid of schizophrenic patients and normal controls. | Q52207888 |
| | Diagnostic criteria and five-year outcome in schizophrenia. A report from the International Pilot Study of schizophrenia | Q52881122 |
| | Intranasal oxytocin reduces psychotic symptoms and improves Theory of Mind and social perception in schizophrenia | Q84759806 |
| P433 | issue | 1-3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| | oxytocin | Q169960 |
| P304 | page(s) | 47-51 | |
| P577 | publication date | 2015-02-09 | |
| P1433 | published in | Schizophrenia Research | Q7431607 |
| P1476 | title | Plasma oxytocin levels predict social cue recognition in individuals with schizophrenia | |
| P478 | volume | 162 | |